A murine monoclonal antibody specific for a cell-surface antigen expressed by a subgroup of human myeloid leukaemias

Gadd, Stephen; Ashman, Leonie K.

doi:10.1016/0145-2126(85)90119-5

Cited by 63 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have reported recently on a murine monoclonal antibody (Mab) that was raised against human acute non-lymphoid leukaemia cells and which i.s specific for a surface antigen on a sub-group of acute myeloid leukaemias (22). The antibody (YB5.B8) detects an anligenic determinant (YB5.B8 antigen) on a 145-150 kilodalton protein which can be immunoprecipitated from solubilized membranes of antigen-positive leukaemia cells (23).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues

et al. 1987

View full text Add to dashboard Cite

Summary.A mouse monoclonal antibody raised against acute myeloid leukaemia cells (YB5.B8 monoclonal antibody; Gadd. S, J. and Ashman, L, K, (1985): Leukaemia Res. 9, 1329-1336) ha,s been found by an indirect immunoperoxidase lechnique to bind lo scattered cells in frozen sections from a number of buman tissues. They have been identified as mast cells in fixed sections of skin, tonsil and duodenum by simultaneous staining of glycosaminoglycan wilh Alcian blue in 0.7 N HCl, The antibody does not distinguish mast cells in mucosal tissues from Ihose in conneclive tissue, altbough ihe level of expression by cells al both sites appears to be heterogeneous. Wilh tbe exception of tow affinity binding lo B lymphocytes, no other bone marrow-derived cells were found to bind the antibody. In particular, basophils and eosinophils were not stained, suggesting that they are not related closely to masi cells and that the antigen detected by YB5.B8 monoclonal aniibody is not an IgE Fc receptor. Therefore, among all mature haemopoieiic lineages, the antibody is specific for mast cells.

show abstract

Section: Introductionmentioning

confidence: 99%

“…S, J. and Ashman, L, K, (1985): Leukaemia Res. 9, 1329-1336) ha,s been found by an indirect immunoperoxidase lechnique to bind lo scattered cells in frozen sections from a number of buman tissues.…”

mentioning

confidence: 99%

Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues

et al. 1987

View full text Add to dashboard Cite

show abstract

“…CD117 is thought to be essential for normal gametogenesis, melanogenesis, hematopoiesis and brain [3][4][5] development, and it is expressed in a variety of normal epithelia, but not in either developing or adult lung tissue. 6,7 This molecule is also consistently expressed in a variety of neoplasms, such as gastrointestinal stromal tumors, 8 seminoma/dysgerminoma, 7 acute myelogenous leukemia, 9 neuroblastoma, 10 Ewing's sarcoma, 11,12 mast cell disorders, 13 and small-cell [14][15][16][17][18][19] or large-cell neuroendocrine carcinoma of the lung. 20 However, data on the prevalence and the clinical implications of CD117 in stage I adenocarcinoma and squamous cell carcinoma are still lacking, and most of the current knowledge on this subject is derived from experiments on cell cultures [21][22][23] or from expression studies of excised tumors, not correlated with clinicopathological features and survival analyses.…”

mentioning

confidence: 99%

CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients

Pelosi

Barisella²,

Pasini

et al. 2004

Modern Pathology

View full text Add to dashboard Cite

CD117, a trans-membrane tyrosine kinase receptor, has been immunolocalized in a large variety of human neoplasms. Little, however, is known about the prevalence and clinical implications of CD117 in stage I adenocarcinoma and squamous cell carcinoma of the lung. We evaluated 201 consecutive stage I adenocarcinoma and squamous cell carcinoma of the lung for CD117 immunoreactivity (dichotomized as negative or positive if containing less than 5% or Z5% immunoreactive neoplastic cells, respectively), also taking into account the pattern (either membranous or cytoplasmic), and the intensity of immunostaining in comparison with intratumoral mast cells. The immunostaining results were then correlated with tumor biopathological characteristics and patients' survival. Membranous CD117 immunoreactivity was documented in 19 (22%) of 88 adenocarcinomas and 15 (13%) of 113 squamous cell carcinomas, whereas cytoplasmic labelling was seen in 28 (32%) adenocarcinomas and eight (7%) squamous cell carcinomas. In both tumor types, membranous or cytoplasmic CD117 immunoreactivity was associated with higher proliferative fraction and with features of more aggressive tumor behavior, including higher stage, size and grade, occurrence of clinical symptoms, high microvessel density and neuroendocrine differentiation. Furthermore, immunoreactive tumors exhibited increased levels of bcl-2, cyclin-E, Her-2, p27Kip1 and fascin, the latter being a marker of tumor cell metastatization in lung cancer. Membranous but not cytoplasmic labelling emerged as an independent risk factor for death and reduced time to progression in adenocarcinoma but not in squamous cell carcinoma patients, when singly adjusted for confounding factors. CD117 immunoreactivity identifies a peculiar subset of stage I adenocarcinoma and squamous cell carcinoma of the lung with highly proliferative tumors and may have prognostic relevance in adenocarcinoma patients. Targeting the CD117 pathway could be a novel therapeutic strategy in a subset of pulmonary carcinomas.

show abstract

“…In particular no transfectants binding the mast celi/AML cell antigen identified by MoAb YB5.B8 (14) or the monocyte antigens detected by MoAbs 4B4, 4B5 and 4C5 (15) have been obtained. This was unlikely to be due to the use of unsuitable (e.g.…”

Section: Discussionmentioning

confidence: 99%

Transfection of genes for human cell surface antigens identified by monoclonal antibodies

et al. 1989

View full text Add to dashboard Cite

Summary Six murine L cell lines expressing five different human cell surface antigens have been prepared by DNA-mediated gene transfer. \.lk~ cells were transfected with calcium phosphate co-precipitates of human genomic DNA and a plasmid containing the Herpes simple.x thymidine kinase gene. After HAT selection, transfectants expressing specific cell surface antigens were identified by in silu immune rosetting using monoclonal antibodies. In this way, transfected cell lines expressing the CD9 antigen, the CD31 antigen (two lines), a unique platelet antigen, an X-linked antigen (RI), and a previously unreported monocyte antigen 11 Dl were prepared. These cell lines have proved useful in the definitive assignment of monoclonal antibodies to specific CD groups. In addition, they provide a source of mRNA for use in expression cloning of the genes for these antigens.

show abstract

A murine monoclonal antibody specific for a cell-surface antigen expressed by a subgroup of human myeloid leukaemias

Cited by 63 publications

References 16 publications

Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues

Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues

CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients

Transfection of genes for human cell surface antigens identified by monoclonal antibodies

Contact Info

Product

Resources

About